caBozantinib in cOllectiNg ductS Renal Cell cArcInoma

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study ID: NCT03354884
Phase: PHASE2
Status: Completed

Conditions

Collecting Duct Carcinoma (Kidney)

Eligibility Criteria

Sex: ALL
Age: 18 Years - 85 Years
Healthy Volunteers: Not accepted

Interventions

cabozantinib — DRUG
cabozantinib 60 mg orally once daily

Study Details

This is a single-arm, phase II trial (monocentric) study designed to determine To evaluate activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria in Metastatic Collecting Duct Renal Cell Carcinoma

Key Dates

Start date: Jan 12, 2018
Status verified: May 2021
Primary completion: Nov 19, 2020
Completion: Nov 19, 2020

Study Design

Enrollment: 23 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Cabozantinib
All subjects will receive open label Cabozantinib 60 mg orally once daily

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 30 Month ]